KR860700251A - 신규한 삼환성 또는 사환성 화합물 및 그 염류의 제조방법 - Google Patents

신규한 삼환성 또는 사환성 화합물 및 그 염류의 제조방법

Info

Publication number
KR860700251A
KR860700251A KR860700202A KR860700202A KR860700251A KR 860700251 A KR860700251 A KR 860700251A KR 860700202 A KR860700202 A KR 860700202A KR 860700202 A KR860700202 A KR 860700202A KR 860700251 A KR860700251 A KR 860700251A
Authority
KR
South Korea
Prior art keywords
group
phenyl
alkyl
same
structural formula
Prior art date
Application number
KR860700202A
Other languages
English (en)
Other versions
KR920003198B1 (ko
Inventor
히또시 우노
미끼오 구로까와
후미노리 사또
나오노부 하타노
Original Assignee
후지와라 도미오
다이니뽄 세이야꾸 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지와라 도미오, 다이니뽄 세이야꾸 가부시끼 가이샤 filed Critical 후지와라 도미오
Publication of KR860700251A publication Critical patent/KR860700251A/ko
Application granted granted Critical
Publication of KR920003198B1 publication Critical patent/KR920003198B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D337/12—[b,e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

신규한 삼환성 또는 사환성 화합물 및 그 염류의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 다음 구조식(Ⅱ)로 표시되는 화합물과 다음 구조식(Ⅱ)으로 표시되는 화합물을 반응시켜 다음 구조식(Ⅰ)로 표시되는 신규한 삼환성(Tricyclic) 또는 사환성(Tetracyclic) 화합물 및 그의 생리적으로 허용 가능한 염류를 제조하는 방법.
    이때 A는 C1-10알킬렌기, Y-Z는, -CH=CH-, -CH2-CH2- 또는, R1은 같거나 다른 수소원자, 할로겐원자, C1-6알킬기, C1-6알콕시기, C1-6알킬티오기나 시아노기, R2는 같거나 다른 수소원자, 할로겐원자, C1-6알킬기, C1-6알콕시기, C1-6알킬티오기나 시아노기, R3는 수소원자, C1-6알킬기 또는 C1-6알콕시기, R4는 페닐기, 알킬부분이 경우에 따라 하나의 수산기로 치환될 수도 있는 페닐-C1-10알킬기, 페닐-C3-5알케닐기, 디페닐메틸기, 나프틸기, 타아조릴기, 경우에 따라 C1-6알콕시카보닐로 치환될 수도 있는 피리딜기, 경우에 따라 C1-6알킬로 치환될 수도 있는 피리미디닐기, 퀴노릴기, 벤조일 -C1-5알킬기, 벤조일기, 푸로일기, 테노일기, 페닐옥시카보닐기, 페닐옥시설포닐기 또는 페닐설포닐기이고, a는 2 또는 3의 정수, b와 c는 각각 1 또는 2의 정수, d는 0-2의 정수를 의미한다. 단, 상기 페닐기, 페닐부분 또는 나프틸기는 경우에 따라 1~2개의 할로겐원자, 수산기, 니트로기, C1-6알킬기, 트리플루오로메틸기, C1-6알콕시기로 치환될 수도 있으며, 2개의 치환기가 존재하는 경우에는 2개가 서로 같을 수도 있고 다를 수도 있다.
    이때, A와 Y-Z,R1,R2,R3,b 및 c는 상기 구조식(Ⅰ) 경우와 같고, X는 알코올의 반응성 에스테르 잔기를 의미한다.
    이때, R4와 a는 상기 구조식(Ⅰ)의 경우와 같다.
  2. 다음 구조식(Ⅳ)로 표시되는 화합물과 다음 구조식(Ⅵ)로 표시되는 화합물을 반응시켜서 다음 구조식(Ⅰ)로 표시되는 신규한 삼환성 또는 사환성 화합물 및 그의 생리적으로 허용가능한 염류를 제조하는 방법.
    이때 A는 C1-10알킬렌기, Y-Z는, -CH=CH-, -CH2-CH2- 또는, R1은 같거나 다른 수소원자, 할로겐원자, C1-6알킬기, C1-6알콕시기, C1-6알킬티오기나 시아노기, R2는 같거나 다른 수소원자, 할로겐원자, C1-6알킬기, C1-6알콕시기, C1-6알킬티오기나 시아노기, R3는 수소원자, C1-6알킬기 또는 C1-6알콕시기, R4는 페닐기, 알킬부분이 경우에 따라 하나의 수산기로 치환될 수도 있는 페닐-C1-10알킬기, 페닐-C3-5알케닐기, 디페닐메틸기, 나프틸기, 타아조릴기, 경우에 따라 C1-6알콕시카보닐로 치환될 수도 있는 피리딜기, 경우에 따라 C1-6알킬로 치환될 수도 있는 피리미디닐기, 퀴노릴기, 벤조일 -C1-5알킬기, 벤조일기, 푸로일기, 테노일기, 페닐옥시카보닐기, 페닐옥시설포닐기 또는 페닐설포닐기이고, a는 2 또는 3의 정수, b와 c는 각각 1 또는 2의 정수, d는 0-2의 정수를 의미한다. 단, 상기 페닐기, 페닐부분 또는 나프틸기는 경우에 따라 1~2개의 할로겐원자, 수산기, 니트로기, C1-6알킬기, 트리플루오로메틸기, C1-6알콕시기로 치환될 수도 있으며, 2개의 치환기가 존재하는 경우에는 2개가 서로 같을 수도 있고 다를 수도 있다.
    T9
    이때, Y-Z와 R1,R2,R3,b 및 c는 상기 구조식(Ⅰ의) 경우와 같다.
    이때, A와 R4및 a는 상기 구조식(Ⅰ)의 경우와 같다.
  3. 다음 구조식(Ⅶ)로 표시되는 화합물과 다음 구조식(Ⅶ)으로 표시되는 화합물을 반응시켜서 다음 구조식(Ⅰ)로 표시되는 신규한 삼환성 또는 사환성 화합물 및 그의 생리적으로 허용가능한 염류를 제조하는 방법.
    이때 A는 C1-10알킬렌기, Y-Z는 -CH=CH-, R1은 같거나 다른 수소원자, 할로겐원자, C1-6알킬기, C1-6알콕시기, C1-6알킬티오기나 시아노기, R2는 같거나 다른 수소원자, 할로겐원자, C1-6알킬기, C1-6알콕시기, C1-6알킬티오기나 시아노기, R3는 수소원자, C1-6알킬기 또는 C1-6알콕시기, R4는 페닐기, 알킬부분이 경우에 따라 하나의 수산기로 치환될 수도 있는 페닐-C1-10알킬기, 페닐-C3-5알케닐기, 디페닐메틸기, 나프틸기, 타아조릴기, 경우에 따라 C1-6알콕시카보닐로 치환될 수도 있는 피리딜기, 경우에 따라 C1-6알킬로 치환될 수도 있는 피리미디닐기, 퀴노릴기, 벤조일 -C1-5알킬기, 벤조일기, 푸로일기, 테노일기, 페닐옥시카보닐기, 페닐옥시설포닐기 또는 페닐설포닐기이고, a는 2 또는 3의 정수, b와 c는 각각 1 또는 2의 정수를 의미한다. 단, 상기 페닐기, 페닐부분 또는 나프틸기는 경우에 따라 1~2개의 할로겐원자, 수산기, 니트로기, C1-6알킬기, 트리플루오로메틸기, C1-6알콕시기로 치환될 수도 있으며, 2개의 치환기가 존재하는 경우에는 2개가 서로 같을 수도 있고 다를 수도 있다.
    이때, R1과 R2,b 및 c는 상기 구조식(Ⅰ) 경우와 같다.
    이때, A와 R2,R4및 a는 상기 구조식(Ⅰ)의 경우와 같다.
  4. 다음 구조식(Ⅰ')로 표시되는 화합물을 산화시켜서 다음 구조식(Ⅰ)로 표시되는 신규한 삼환성 또는 사환성 화합물 및 그의 생리적으로 허용가능한 염류를 제조하는 방법.
    이때 A는 C1-10알킬렌기, Y-Z는, R1은 같거나 다른 수소원자, 할로겐원자, C1-6알킬기, C1-6알콕시기, C1-6알킬티오기나 시아노기, R2는 같거나 다른 수소원자, 할로겐원자, C1-6알킬기, C1-6알콕시기, C1-6알킬티오기나 시아노기, R3는 수소원자, C1-6알킬기 또는 C1-6알콕시기, R4는 페닐기, 알킬부분이 경우에 따라 하나의 수산기로 치환될 수도 있는 페닐-C1-10알킬기, 페닐-C3-5알케닐기, 디페닐메틸기, 나프틸기, 타아조릴기, 경우에 따라 C1-6알콕시카보닐로 치환될 수도 있는 피리딜기, 경우에 따라 C1-6알킬로 치환될 수도 있는 피리미디닐기, 퀴노릴기, 벤조일 -C1-5알킬기, 벤조일기, 푸로일기, 테노일기, 페닐옥시카보닐기, 페닐옥시설포닐기 또는 페닐설포닐기이고, a는 2 또는 3의 정수, b와 c는 각각 1 또는 2의 정수를 의미한다. 단, 상기 페닐기, 페닐부분 또는 나프틸기는 경우에 따라 1~2개의 할로겐원자, 수산기, 니트로기, C1-6알킬기, 트리폴루로라메틸기, C1-6알콕시기로 치환될 수도 있으며, 2개의 치환기가 존재하는 경우에는 2개가 서로 같을 수도 있고 다를 수도 있다.
    이때, A와 R1,R2,R3,R4,a,b 및 c는 상기 구조식의 경우와 같다.
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860700202A 1984-08-10 1985-08-09 신규한 삼환성 또는 사환성 화합물 및 그 염류의 제조방법 KR920003198B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP59-168532 1984-08-10
JP59168532A JPS6147466A (ja) 1984-08-10 1984-08-10 アミン誘導体
PCT/JP1985/000445 WO1986001203A1 (en) 1984-08-10 1985-08-09 Tryciclic or tetracyclic compounds, process for their preparation, and medicinal composition containing them

Publications (2)

Publication Number Publication Date
KR860700251A true KR860700251A (ko) 1986-08-01
KR920003198B1 KR920003198B1 (ko) 1992-04-24

Family

ID=15869764

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860700202A KR920003198B1 (ko) 1984-08-10 1985-08-09 신규한 삼환성 또는 사환성 화합물 및 그 염류의 제조방법

Country Status (11)

Country Link
US (1) US4749703A (ko)
EP (1) EP0191867B1 (ko)
JP (1) JPS6147466A (ko)
KR (1) KR920003198B1 (ko)
AT (1) ATE68484T1 (ko)
AU (1) AU572690B2 (ko)
CA (1) CA1265788A (ko)
DE (1) DE3584442D1 (ko)
DK (1) DK168918B1 (ko)
MX (1) MX9202782A (ko)
WO (1) WO1986001203A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8500273D0 (sv) * 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
FI91401C (fi) * 1987-03-17 1994-06-27 Hoechst Roussel Pharma Menetelmä terapeuttisesti aktiivisten substituoitujen 9-aminotetrahydroakriinien ja niille läheisten yhdisteiden valmistamiseksi
US4882351A (en) * 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
US4994463A (en) * 1987-12-14 1991-02-19 Kyowa Hakko Kogyo Co., Ltd. Tricyclic thromboxane A2 antagonists
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
JP2618195B2 (ja) * 1991-09-24 1997-06-11 大日本製薬株式会社 血中脂質代謝改善剤
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
KR100502229B1 (ko) * 1995-02-28 2005-11-08 다이이찌 산토리 파마 가부시키가이샤 아릴피페리딘및아릴피페라진유도체,및이를함유하는약제
TWI267511B (en) * 1999-06-03 2006-12-01 Lilly Co Eli Process for preparing 10,11-methanobenzosuberane derivatives
EP1509213A2 (en) * 2002-05-23 2005-03-02 Abbott Laboratories Acetamides and benzamides that are useful in treating sexual dysfunction
CA2521330A1 (en) * 2003-04-08 2004-10-21 Neuromed Technologies, Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB210533A (en) * 1922-11-02 1924-02-04 Reginald Charles Reid Improvements in or relating to apparatus for grinding and polishing lenses and the like
US3954777A (en) * 1970-03-03 1976-05-04 Zambon S.P.A. Aminopropionyl derivatives of 2,3-diphenyl cyclopropylamine
JPS553353B1 (ko) * 1971-04-10 1980-01-24
GB1347935A (en) * 1971-04-10 1974-02-27 Yoshitomi Pharmaceutical Piperazine derivatives methods for their production and phar maceutical compositions containing them
IT1054961B (it) * 1976-01-23 1981-11-30 Corvi Camillo Spa Derivati della piperazina adatti come agenti anti ulcera
JPS6059177B2 (ja) * 1978-06-24 1985-12-24 日本電信電話株式会社 無水石英ガラスの製造方法
CS210369B1 (cs) * 1980-10-01 1982-01-29 Miroslav Rajsner Nové deriváty 6,11-dihydrodibenzo(b,e)thiepin-5,5-dioxidu, jejich soli a způsob jejich přípravy
ZA825719B (en) * 1981-09-03 1983-06-29 Recordati Chem Pharm Alkanoylanilides
JPS5896075A (ja) * 1981-12-03 1983-06-07 Hokuriku Seiyaku Co Ltd １−アミノカルボニルエチル置換ピペラジン及びホモピペラジン誘導体
US4457931A (en) * 1982-09-27 1984-07-03 Selvi & C. S.P.A. Piperazine derivatives with anticholinergic and/or antihistaminic activity

Also Published As

Publication number Publication date
WO1986001203A1 (en) 1986-02-27
DK168918B1 (da) 1994-07-11
DE3584442D1 (de) 1991-11-21
KR920003198B1 (ko) 1992-04-24
DK160686D0 (da) 1986-04-09
DK160686A (da) 1986-04-09
AU4721985A (en) 1986-03-07
AU572690B2 (en) 1988-05-12
EP0191867A4 (en) 1987-09-02
JPH0358341B2 (ko) 1991-09-05
MX9202782A (es) 1992-06-30
ATE68484T1 (de) 1991-11-15
JPS6147466A (ja) 1986-03-07
US4749703A (en) 1988-06-07
EP0191867A1 (en) 1986-08-27
EP0191867B1 (en) 1991-10-16
CA1265788A (en) 1990-02-13

Similar Documents

Publication Publication Date Title
KR860700251A (ko) 신규한 삼환성 또는 사환성 화합물 및 그 염류의 제조방법
KR870010030A (ko) 치환된 벤즈아미드 유도체, 그 제조방법 및 이를 함유하는 약학적 조성물
KR900014358A (ko) 2-(1-피페라진일)-4-페닐시클로알카노피리딘 유도체, 그들의 제조방법 및 그들을 함유하는 약학적 조성물
KR880013888A (ko) 신규 디티오아세탈 화합물, 그의 제조방법 및 이 화합물로 되는 제약 조성물
KR960702460A (ko) 티아졸리딘디온 및 이것을 함유하는 약제(new thiazolidindiones and drugs containing them)
KR890012970A (ko) 테트라히드로 이소퀴놀린 유도체
KR960022486A (ko) 신규 티아졸리딘-4-온 유도체
KR930016436A (ko) 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물
KR900016098A (ko) 카페인산의 유도체 및 이를 함유하는 약제학적 조성물
SE7710873L (sv) Nya 1h-pyrazolo(3,4-b)pyridiner
ES8609225A1 (es) Un procedimiento para preparar un derivado de semicarbazida
KR910000711A (ko) 크로만 유도체
KR860008973A (ko) 2-피롤리돈 유도체
ES557079A0 (es) Un procedimiento para la preparacion de derivados de 1,5-benzotiazepina
KR900006301A (ko) 1,4-디아자비사이클로[3.2.2]노난의 제조방법
KR910020004A (ko) 이소크로만 유도체
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR860002508A (ko) 푸로(3,2-c)피리딘 유도체, 그의 제법 및 그를 포함하는 의약 조성물
KR890009901A (ko) 3-히드록시-2-(4-메톡시페닐)-5-(2-메틸아미노에틸)-2,3-디히드로-5h-1,5- 벤조티아제핀-4-온 유도체, 그의 제조 및 치료에의 이용
YU158385A (en) Process for obtaining derivatives of 2-pyridine thioles
PT96003A (pt) Processo para a preparacao de composicoes farmaceuticas, contendo um derivado triazol
SE8703494D0 (sv) Mellanprodukter anvendbara vid framstellning av 2-tiofen-ettiksyraderivat
HU895651D0 (en) Process for the preparation of substituted 3-amino-nonimine derivatives and pharmaceutical compositions containing said compounds
FR2452495A1 (fr) 2-epi-fortimicines a et b et leurs derives, utiles notamment comme antibiotiques, et intermediaires pour leur preparation
KR920002564A (ko) N-알킬 티아졸리딘 유도체

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19980403

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee